| Name | Title | Contact Details |
|---|
QualCare, Inc., one of the region`s leading providers of health care coverage, provides the public and private marketplace with a higher-quality, lower-cost alternative to commercial insurance companies. QualCare`s network covers over 100 acute, specialty and rehabilitation hospitals, as well as over 31,000 physicians and other ancillary providers across New Jersey, New York and Pennsylvania. Founded in 1991 from a consortium of hospital systems, QualCare has experienced dramatic growth over the past two decades. Currently, 16 of New Jersey`s largest and most successful hospitals own and serve on QualCare`s Board of Directors. QualCare services over 900,000 members, with a clientele that spans health systems, unions, local governments, school boards, small to large businesses and some of New Jersey`s largest corporations. With rate increases that are consistently below industry standards and unparalleled service satisfaction, QualCare is well positioned to succeed in the changing healthcare industry.
The Medical Affairs Company is a Kennesaw, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Healthcare Purchasing Alliance (HPA) is a Orlando, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Value Drug Company, founded in 1934 and incorporated in 1936, is a wholesale purchasing cooperative of Independent Pharmacies.
Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company’s products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections. It is also developing SYR-472, which is in Phase III clinical trials for the treatment of Type-2 diabetes. In addition, the company has rights to compounds in various stages of development and commercialization, which includes Nesina, Liovel, Oseni, and Kazano for the treatment of Type-2 diabetes, as well as Priligy for the treatment of premature ejaculation. The company was founded in 1998 and is headquartered in Morrisville, North Carolina.